Sotorasib, an irreversible KRAS G12C inhibitor, demonstrated a modest clinical activity as single agent in G12C-mutated CRC patients who previously received standard treatments including fluoropyrimidine, oxaliplatin, and irinotecan (15). This evidence concerns the gene KRAS and colorectal carcinoma.